A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year Psychedelics Investing
Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial Psychedelics Investing
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Psychedelics Investing
Optimi Health Secures Ibogaine Supply and Commences Finished Drug Product Development Psychedelics Investing
Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia Psychedelics Investing
Optimi Health Welcomes Expanded Psychedelic-Assisted Therapy Access Under Updated Authorized Prescriber Framework in Australia Psychedelics Investing
Compass Pathways to Participate in Jefferies Global Healthcare Conference on June 3, 2026 Psychedelics Investing
Optimi Health Announces Closing of Oversubscribed US$15 Million Public Offering Psychedelics Investing
Optimi Health Announces Pricing of Oversubscribed US$15 Million Public Offering and Nasdaq Uplisting Psychedelics Investing
Compass Pathways to Participate in RBC Capital Markets Global Healthcare Conference on May 19-20, 2026 Psychedelics Investing
